Balko named Waddell Walker Hancock Cancer Discovery Fund Scholar
Dr. Justin Balko received funds for a project to improve antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Year in Review 2024: Appointments strengthen Medical Center’s missions
Numerous additions and appointments during the past year are enhancing Vanderbilt University Medical Center’s missions.
Nine Department of Medicine faculty selected for membership in Academy for Excellence in Clinical Medicine
Nine faculty in four different divisions are among the 25 new faculty selected for membership in Vanderbilt University School of Medicine's Academy for Excellence in Education.
Potential treatment eyed for abnormal blood cell disorder
Researchers at Vanderbilt University Medical Center, including Department of Medicine Drs. Alex Bick (senior author), Brett Heimlich, Brent Ferrell, Ashwin Kishtagari and Michael Savona, have identified key factors that contribute to the clonal growth of abnormal blood cells experienced by roughly one in 10 people over age 70.
Five Department of Medicine faculty among world's most "highly cited" researchers
Eleven current Vanderbilt University faculty members are included in the 2024 list of “Highly Cited Researchers” around the world whose papers have been cited most frequently by other scientists.
Only half of young cancer patients report discussing fertility preservation
Information was gathered by investigators with the Reproductive Health After Cancer Diagnosis and Treatment (REACT) study, an initiative led by Andreana Holowatyj, PhD, MSCI, Assistant Professor of Medicine, Division of Epidemiology.
Michael Gibson votes with FDA panel to limit immunotherapy indication
The panel determined that allowing the wider indication would put patients at risk for adverse reactions from the two immunotherapies but without the added benefit in survival.
Tae Kon Kim receives V Foundation grant for MDS drug research
The V Foundation for Cancer Research has awarded a $600,000 grant to Tae Kon Kim, MD, PhD, assistant professor of Medicine (Hematology and Oncology). Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS.
Eng named VICC associate director of Strategic Relations and Research Partnerships
In this new position Cathy Eng, MD (Hematology and Oncology), the David H. Johnson Professor of Surgical and Medical Oncology, will elevate Vanderbilt-Ingram’s profile locally, regionally, nationally and internationally through stakeholder engagement, programmatic development and targeted marketing.
‘Off-the-shelf’ CAR T therapy shows promise for relapsed/refractory multiple myeloma
Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or “off-the-shelf” chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who have not responded to existing treatments or who have relapsed.